Detail akcie NanoGroup Br online

Business Summary: Nanogroup SA is a Poland-based company engaged in the biotechnology sector. The Company focuses on the investment in, as well as development of advanced biotechnological projects in the areas of cancer prevention, early diagnosis, targeted cancer therapies and ontological rehabilitation. Its projects portfolio includes NanoVelos, which is responsible for the creation of drug delivery system for proven oncologic medicines to optimize their performance; NanoSanguis, which develops artificial blood to keep alive patients wounded in accidents, as well as a system, named Organ farm, to preserve human organs ex vivo, and NanoThea, which is dedicated to technology that detects cancer cells in early stage.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Nanogroup SA revenues decreased 99% to PLN2K. Net loss increased from PLN839K to PLN7.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Other Costs increase from PLN839K to PLN13.2M (expense), Labor & Related Expenses in SGA increase of 4% to PLN2.4M (expense).